Incidence of the major cytogenetic risk groups* in various studies.
| Karyotype . | Döhner et al. 2000 n=325 . | CLL1** n=230 . | CLL3*** n=113 . |
|---|---|---|---|
| * According to the hierarchical model of chromosome aberrations in CLL as proposed by Döhner et al. (2000)6 | |||
| ** CLL1 trial of the German CLL Study Group (GCLLSG) for Binet A patients | |||
| *** CLL3 trial of the GCLLSG evaluating high-dose therapy followed by autologous hematopoietic stem cell transplantation | |||
| 17p deletion | 23 (7%) | 14 (6%) | 4 (4%) |
| 11q deletion | 56 (17%) | 20 (9%) | 25 (22%) |
| trisomy 12 | 47 (14%) | 22 (10%) | 13 (11%) |
| normal karyotype | 57 (18%) | 52 (22%) | 21 (19%) |
| 13q deletion single | 117 (36%) | 99 (43%) | 35 (31%) |
| various aberrations | 25 (8%) | 23 (10%) | 15 (13%) |
| Karyotype . | Döhner et al. 2000 n=325 . | CLL1** n=230 . | CLL3*** n=113 . |
|---|---|---|---|
| * According to the hierarchical model of chromosome aberrations in CLL as proposed by Döhner et al. (2000)6 | |||
| ** CLL1 trial of the German CLL Study Group (GCLLSG) for Binet A patients | |||
| *** CLL3 trial of the GCLLSG evaluating high-dose therapy followed by autologous hematopoietic stem cell transplantation | |||
| 17p deletion | 23 (7%) | 14 (6%) | 4 (4%) |
| 11q deletion | 56 (17%) | 20 (9%) | 25 (22%) |
| trisomy 12 | 47 (14%) | 22 (10%) | 13 (11%) |
| normal karyotype | 57 (18%) | 52 (22%) | 21 (19%) |
| 13q deletion single | 117 (36%) | 99 (43%) | 35 (31%) |
| various aberrations | 25 (8%) | 23 (10%) | 15 (13%) |